Iksuda

Creating class-leading ADCs with enhanced tumor specificity

Iksuda Therapeutics creates class-leading antibody-drug conjugates (ADCs) with enhanced tumor specificity for hard-to-treat cancers. The company builds an ADC pipeline centered on tumor-selective payload release and activation, enabled by multiple in-house platforms and payload series.

Partnerships